RENEURON GRP (LSE:RENE)

 

RENEURON GRP (RENE.L, LSE, LSE:RENE)

RENE Share PerformanceMore

52 week high4.3900 02/12/14
52 week low2.7100 23/12/13
52 week change 0.3000 (9.38%)
4 week volume18,077,967 24/11/14

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

ReNeuron widens H1 pretax loss

ReNeuron has widened its H1 pretax loss to 4.9m, from a year-earlier loss of 3.5m. Revenue was 11,000, flat on the year. Chai...

Interim Results

RNS Number: 1655X ReNeuron Group plc 17 November 2014 Details are given below of an analyst meeting and webcast at 10.00am this morning 17 November 2014 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Interim Results for the six months ended 30 September 2014 Guildford, UK, 17 November 2014: ReNeuron Group plc (AIM: RENE), a ...

Notification of Interim Results

RNS Number: 6549V ReNeuron Group plc 30 October 2014 30 October 2014 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Notification of Interim Results ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, will announce its interim results for the six months ended 30 September 2014 on Monday 17 November 20...

Notification of Major Interest in Shares

RNS Number: 1849U ReNeuron Group plc 14 October 2014 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ReNeuron Group plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acqui...

Directors' Interest in Shares and Share Options

RNS Number: 1979S ReNeuron Group plc 22 September 2014 22 September 2014 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Directors' Interest in Shares and Share Options Guildford, UK, 22 September 2014: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, today announces that on 19 September 2014 , the fo...

Block Listing Six Monthly Review

RNS Number: 6817R ReNeuron Group plc 15 September 2014 15 September 2014 AIM: RENE ReNeuron Group plc Block Listing Six Monthly Review Name: ReNeuron Group plc Name of Scheme: Share-based payment agreements Period of Return: From 14 March 2014 to 12 September 2014 Balance of unallotted securities under scheme(s) from previous return: 1,645,7...

New CEO appointed at ReNeuron Group

ReNeuron Group (AIM: RENE), a UK-based stem cell therapy company, has announced that Olav Helleb, is to become its ...

Appointment of CEO

RNS Number: 0192R ReNeuron Group plc 08 September 2014 8 September 2014 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Appointment of Chief Executive Officer Guildford, UK, 8 September 2014: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, announces the appointment of Olav Helleb, a highly exper...

Fundamental DataMore

EPS-0.5
Dividend yield0 %

Equity Research (RENE)

edison investment research
ReNeuron Group plc
28/11/2014
ReNeuron is facing a potentially transformational year in 2015, with key clinical data and relocation to a new cell manufacturing/research facility. Its allogeneic, CTX neural stem cell product is...
edison investment research
ReNeuron Group plc
29/09/2014
ReNeuron operates off solid fundamentals as it seeks to advance its novel stem cell technology. Last year’s £25.3m fundraise coupled with a £7.8m grant from the Welsh government to build a new...
edison investment research
ReNeuron Group plc
08/05/2014
Long-term data from the PISCES Phase I study of ReNeuron’s neural stem cell product ReN001 in 11 disabled stroke patients provide further evidence of safety and encouraging signals of efficacy. The...

Users' HoldingsMore

Users who hold RENEURON GRP also hold..
BARCLAYS13%
BP13%
LLOYDS BANKING GRP11%
ROYAL BANK OF SCOTLAND GROUP11%
FALKLAND OIL & GAS11%